ZhouFYuTDuR, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet2020; 395(10229): 1054–1062.
2.
BrownleeWBourdetteDBroadleyS, et al. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. Epub ahead of print 2020. DOI: 10.1212/WNL.0000000000009507.
3.
ColesAJTwymanCLArnoldDL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380(9856): 1829–1839.
4.
BiancoAMariP-VLariciAR, et al. Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients. Mult Scler Relat Disord2020; 37: 101450.
5.
LiZRichardsSSurksHK, et al. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol2018; 194(3): 295–314.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
